Abvc biopharma medical device vitargus receives taiwan national innovation award

Fremont, ca, dec. 15, 2021 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that vitargus®, its vitreous substitute intended to facilitate retina re-attachment surgery, received the 2021 “national innovation and renewal of diligence” award from the institute for biotechnology and medicine industry (ibmi) of taiwan. the award was presented at the taiwan medical technology exhibition on december 2, 2021 at the taipei nangang exhibition center.
ABVC Ratings Summary
ABVC Quant Ranking